BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Two in Three Cancer Patients Are Non-Adherent With Their Medications, According to Kantar Health Research


5/21/2013 9:40:34 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, May 21, 2013—Two-thirds of patients who have been diagnosed with leukemia, melanoma or non-small cell lung cancer reported that they engage in at least one type of non-adherent behavior in their medicine use, according to new findings from the National Health and Wellness Survey (NHWS), conducted by Kantar Health. The research will be presented today at the 18th Annual International Meeting for ISPOR (International Society for Pharmacoeconomics and Outcomes Research) in New Orleans.

“Cancer treatment is rapidly evolving with the emergence of highly effective oral targeted therapies, which has increased the importance of patients being adherent with their medications,” said Marco DiBonaventura, Ph.D., vice president, health outcomes, with Kantar Health. “When looking at adherence from a patient’s perspective among those with a type of cancer where oral therapies are the standard of care, we found that a significant number engaged in some type of non-adherent behavior—such as forgetting to take their medicine or not taking their medication as directed—which resulted in worse outcomes and higher healthcare resource use.”

Cancer patients who were non-adherent had significantly worse mental health status, and tended to have been hospitalized and visited the emergency room more often than adherent patients.

“The results of our survey suggest that non-adherence among these cancer patients may result in mental health impairments and possibly greater resource use,” DiBonaventura said. “As more oral targeted therapies emerge in oncology, pharma companies should emphasize improving adherence rates to maximize the benefits of these treatments for patients and to reduce societal costs.”

Visit Kantar Health’s website to download the full poster, “Adherence and Its Association with Health Outcomes among Patients Currently Treated for Leukemia, Melanoma or Non-Small Cell Lung Cancer (NSCLC).”

About the National Health and Wellness Survey (NHWS)

The study’s results were drawn from the 2012 U.S. NHWS, a nationally representative, self-administered survey conducted annually. Topics covered include the health status, attitudes, behaviors and outcomes among adults 18 or older.

Kantar Health conducts the NHWS in the U.S., Europe, Asia and Latin America. The survey is the largest self-reported dataset in the healthcare industry.

About Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.

Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from pre-clinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit www.kantarhealth.com.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES